Transcatheter aortic valve implantation: the evidence is catching up with reality
Key result
Two large European registries of transcatheter aortic valve implantation in high-risk patients demonstrated a 98-99% technical success rate and a 30-day mortality of 12%.
Population
Mainly octogenarians with severe aortic stenosis, high prevalence of coronary and peripheral vascular…
Design
Editorial
Follow-up
1 month
Authors
Discussion
Loading...
Member takes
Implication
This editorial highlights that while TAVI has high technical success in real-world registries, the 30-day mortality and complication rates underscore the need for standardized outcome definitions and randomized clinical trials.
Structured PICO
P
Population
Editorial summarizing two large European registries of TAVI in high-risk patients with severe aortic stenosis, reporting 30-day outcomes.
I
Intervention
Transcatheter aortic valve implantation (TAVI) using Edwards Sapien balloon-expandable prosthesis or Medtronic CoreValve self-expanding device via transfemoral, transapical, or trans-subclavian access
This editorial highlights that while TAVI has high technical success in real-world registries, the 30-day mortality and complication rates underscore the need for standardized outcome definitions and randomized clinical trials.
Limitations
- Devices and access routes used at operator discretion
- Only short-term clinical outcome data at 1 month
- Data becomes outdated with new device iterations
- Lack of data monitoring and independent event adjudication
- Inconsistent outcome definitions
Cite This Study
Buellesfeld et al. (2010) conducted an editorial in Severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) was evaluated on 30-day mortality. Two large European registries of transcatheter aortic valve implantation in high-risk patients demonstrated a 98-99% technical success rate and a 30-day mortality of 12%.